Analysts update price targets of NuVasive stock — 3 quick points

Spinal Tech

Analysts have updated their price targets for NuVasive shares, according to Fiscal Standard.

Here are three quick points:

 

1. Jeffries analysts reiterated their "buy" rating for NuVasive stock with a price target of $72, on July 27.

 

2. Barclays analysts reiterated their "overweight" rating for NuVasive shares with a price target of $71, on July 27.

 

3. On July 27, Brean Capital analysts reiterated their "buy" rating for NuVasive stock with a price target of $70.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers